Rhythm Control Versus Rate Control for New Onset Atrial Fibrillation

Rhythm Control Versus Rate Control for New Onset Atrial Fibrillation After Non-cardiac Non-thoracic Surgery

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05950971

Enrollment

Registered

2023-07-18

Start date

2021-07-01

Completion date

2022-01-21

Last updated

2023-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation New Onset, Atrial Fibrillation Paroxysmal

Brief summary

Adult patients who are diagnosed new onset atrial fibrillation with rapid ventricular response within 7 days after non-cardiac non-thoracic surgery are enrolled.

Detailed description

After randomization, they are allocated to rhythm control strategy group or rate control strategy group. In rhythm control strategy group, patients are given amiodarone primarily for the purpose of sinus conversion of cardiac rhythm. In rate control strategy group, patients are given diltiazem or esmolol for the purpose of rate control. the rate of sinus conversion within 48 hours after treatment are compared.

Interventions

DRUGAmiodarone, diltiazem or esmolol

Intravenous continuous infusion after loading or bolus dose of amiodarone, diltiazem or esmolol.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Intervention model description

Single blinded randomized controlled trial

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Older than 18 years * Newly diagnosed atrial fibrillation or flutter * Patients with atrial fibrillation or flutter that occurred within 7 days after non-cardiac non-thoracic surgery * Atrial fibrillation or flutter with rapid ventricular response(HR ≥110/min) * Patients without hemodynamic instability (MBP≥65mmHg with norepinephrine continuous infusion less than 5mcg/min or without vasopressor support)

Exclusion criteria

* Atrial fibrillation or flutter prolonged more than 48 hours without anticoagulation * Patients who have decreased cardiac function or heart failure (EF \<40%) * Patients who have cardiac conduction disorder, QT prolongation(QTc ≥500ms)

Design outcomes

Primary

Measure	Time frame	Description
Rate of sinus conversion	within 48 hrs	Rate of sinus conversion within 48 hours

Secondary

Measure	Time frame	Description
Time to first sinus conversion	during the same admission period	Time to first sinus conversion
Recurrence of atrial fibrillation	during the same admission period	Recurrence of atrial fibrillation during the same admission period

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026